Therma Bright Secures Major Distribution Deals for Medicare-Approved Compression Device
Medical device company Therma Bright has secured significant purchase orders for its Venowave VW5 compression device, marking a substantial expansion in the $4.2 billion compression therapy market following Medicare approval and reimbursement authorization.
Following Medicare reimbursement approval, Therma Bright Inc. has secured purchase orders for 1,850 Venowave VW5 devices in January alone, positioning the company for significant growth in the compression therapy market. The orders, valued at over $1.5 million, come from major distributors including DME Authority and Valor Medical, signaling strong market acceptance of the company's innovative mobile compression device.
The company's recent success stems from receiving a permanent Healthcare Common Procedure Coding System (HCPCS) code from Medicare, making the Venowave VW5 the only Medicare-approved, reimbursable, mobile mechanical compression system in the US. This designation has opened doors to substantial distribution opportunities, with DME Authority committing to potential purchases of up to $12 million in devices through 2025.
These developments are particularly significant for the healthcare sector, as the global compression therapy market is projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033. The Venowave VW5, being a lightweight, battery-operated device for treating poor circulation in lower extremities, addresses a critical medical need while offering mobility advantages over traditional compression solutions.
The successful pilot programs and rapid reimbursement experiences reported by distributors suggest strong market potential for the device. Valor Medical, for instance, reports receiving approximately 100 doctor referrals daily for vascular compression therapy solutions, indicating substantial ongoing demand. The company's ability to secure 100% reimbursement through Medicare demonstrates the product's alignment with healthcare providers' needs and insurance requirements.
Further enhancing its market position, Therma Bright is also pursuing FDA classification for its acoustic AI Digital Cough Technology, potentially opening additional revenue streams in the remote therapeutic monitoring space. This diversification could strengthen the company's role in the medical device market while addressing emerging healthcare needs.